About: pharma companies
OpinionPromoted content
Drugs incentives have saved lives in Europe
Without strong incentives to spur continued investment in medical innovation, we cannot hope to ensure the sustainability of European healthcare systems and fulfil the promise of our great union, writes Jan Fischer.Pharma industry ‘cannot escape’ drug price talks, say patient groups
Patient groups and the pharmaceutical sector agree that access to medicines needs to be improved - but the way to do it seems to divide them. EURACTIV.com reports from Sofia.EU drugs agency to unveil results on ‘early medicines’ project this week
The European Medicines Agency (EMA) will this week publish the much-awaited results of a pilot project on the early marketing authorisation of drugs, EURACTIV has learnt.A new debate is needed for biopharmaceuticals
The increasing complexity and uncertainty of drug development is hampering the industry’s ability to discover new, life-changing innovative medicines, writes Stefan Gijssels.Berlin launches dialogue to boost pharma research
The German government initiated plans on Monday (15 September) to strengthen the country’s attractiveness for pharmaceutical research and development, but the Left Party warns it is likely to become an "image campaign" for pharmaceutical giants. EURACTIV.de reports. VideoPromoted content